alemtuzumab + CHOP

Alemtuzumab + CHOP (C-CHOP) is an investigational chemo-immunotherapy combination regimen consisting of the monoclonal antibody alemtuzumab (Campath) and the standard CHOP chemotherapy backbone (cyclophosphamide, doxorubicin, vincristine, and prednisone). Developed by researchers at Weill Medical College of Cornell University, this regimen was evaluated in a Phase I dose-escalation trial for the treatment of aggressive T-cell, null-cell, and NK-cell lymphomas. Alemtuzumab targets the CD52 antigen, which is highly expressed on the surface of malignant T-cells and NK-cells, while the CHOP components provide broad cytotoxic activity through DNA damage and inhibition of mitosis. Although the combination aimed to improve response rates in these rare lymphoma subtypes, its clinical development was significantly limited by severe treatment-related toxicities, including profound immunosuppression and high rates of infectious complications such as cytomegalovirus (CMV) reactivation.

Other names

CHOP plus alemtuzumabCampath plus CHOPalemtuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone